European CHMP recommends approval of Obiltoxaximab SFL for treatment or post-exposure prophylaxis of inhalational anthrax

Obiltoxaximab is a monoclonal antibody that binds to the protective antigen (PA) of Bacillus anthracis toxin, thereby inhibiting binding of PA to its cellular receptors and preventing intracellular entry of the toxin components. Final approval is awaited.

European Medicines Agency